Pyrotinib

Generic Name: Pyrotinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₂H_₃₁ClN_₆O_₃

CAS Number: 1269662-73-8

Unique Ingredient Identifier: CJN36EQM0H

Background: Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Pyrotinib in HER2-positive Early Breast Cancer

Not Applicable

Not yet recruiting

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Pyrotinib

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-11

Lead Sponsor: Nie Jianyun

Target Recruit Count: 156

Registration Number: NCT06718335

Study of SHR-A1811 Combined with Pyrotinib and Bevacizumab in Advanced Breast Cancer with Brain Metastasis

Phase 1

Not yet recruiting

Conditions: Breast Cancer Metastatic
Breast Cancer Brain Metastases

Interventions: Drug: SHR-A1811
Drug: Pyrotinib
Drug: Bevacizumab

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-05

Lead Sponsor: Fudan University

Target Recruit Count: 74

Registration Number: NCT06718933

Locations: 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

First Posted Date: 2024-11-18

Last Posted Date: 2024-11-18

Lead Sponsor: Peking University Shenzhen Hospital

Target Recruit Count: 200

Registration Number: NCT06692491

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Phase 2

Recruiting

Conditions: Mutation
Lung Cancer Stage III

Interventions: Drug: Glecirasib
Drug: Dabrafenib+Trametinib
Drug: Larotrectinib
Drug: Crizotinib
Drug: Sunvozertinib
Drug: Pralsetinib
Drug: Savolitinib
Drug: Pyrotinib
Drug: Ensartinib

First Posted Date: 2024-08-21

Last Posted Date: 2024-12-10

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 120

Registration Number: NCT06563999

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

Not Applicable

Not yet recruiting

Conditions: Breast Cancer
RWS
Pyrotinib

Interventions: Drug: Pyrotinib

First Posted Date: 2024-07-10

Last Posted Date: 2024-07-10

Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Target Recruit Count: 500

Registration Number: NCT06495541

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

Phase 3

Recruiting

Conditions: First-line Treatment
HER2-positive Metastatic Breast Cancer

Interventions: Drug: disitamab vedotin
Drug: trastuzumab
Drug: Pyrotinib
Drug: Pertuzumab
Drug: taxane drug

First Posted Date: 2024-02-26

Last Posted Date: 2024-02-26

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 312

Registration Number: NCT06278870

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China

A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Neoplasm Female

Interventions: Drug: Docetaxel
Drug: Carboplatin
Drug: Inetetamab
Drug: Pyrotinib

First Posted Date: 2024-01-31

Last Posted Date: 2024-01-31

Lead Sponsor: Wang Ouchen

Target Recruit Count: 154

Registration Number: NCT06234137

Locations: 🇨🇳
the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Phase 4

Recruiting

Conditions: Advanced Breast Cancer
HER2-positive Breast Cancer

Interventions: Drug: Pyrotinib
Drug: Trastuzumab
Drug: Taxanes
Drug: Capecitabine

First Posted Date: 2024-01-22

Last Posted Date: 2024-02-28

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 100

Registration Number: NCT06217185

Locations: 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Phase 2

Not yet recruiting

Conditions: Disitamab Vedotin
ERBB2 Mutation-Related Tumors
Non Small Cell Lung Cancer
ERBB2 Gene Duplication

Interventions: Drug: Disitamab Vedotin
Drug: third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib)
Drug: pyrotinib

First Posted Date: 2023-12-29

Last Posted Date: 2023-12-29

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 108

Registration Number: NCT06185400

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

Phase 3

Recruiting

Conditions: Breast Cancer Invasive

Interventions: Drug: pyrotinib

First Posted Date: 2023-06-18

Last Posted Date: 2023-11-21

Lead Sponsor: RenJi Hospital

Target Recruit Count: 488

Registration Number: NCT05910398

Locations: 🇨🇳
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy